🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

RecruitingNAAges 18 Years - anyAllRambam Health Care Campus
NCT07384013 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult oncology patients (≥18 years old). * Receiving apixaban or rivaroxaban for anticoagulation. * New/current metamizole users taking at least 1g TID for pain management. * Platelets ≥100×10⁹/L * ECOG PS\<3 * Provided informed consent Exclusion Criteria: * History of allergic reaction to metamizole or DOACs. * Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT/zonda)
💊

What it tests

  • metamizole
  • metamizole
📍

Where

1 site
Rambam Health Care Campus
Haifa, Israel
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy